BCL6 peptide inhibitor (Weill Medical College of Cornell University)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameBCL6 peptide inhibitor (Weill Medical College of Cornell University)
Drug Alias NameBCL6 Peptide Inhibitor (Albert Einstein College of Medicine)retro-inverso peptidomimetic inhibitor (Albert Einstein College of Medicine)RI-BPI
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionB-cell lymphoma 6 protein inhibitors
TargetsB-cell lymphoma 6 protein
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlbert Einstein College Of Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWeill Medical College of Cornell UniversityAlbert Einstein College Of Medicine Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Large B-Cell, DiffuseNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A